EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 3.0

Phase I Study Evaluating Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Recombinant Human Serum Albumin (rHSA) in Healthy Adults

Veerendra Kumar Panuganti, Mamatha Reddy Dundigalla, Venkata Ramalingayya Grandhi, Sridevi Khambhampaty, Pavan Kumar Madala, Javeed Mohammad iD, Althaf Shaik, Mahaboob Basha Shaik, Sanyasirao Kssvv, Sai Kumar Sangeetham

Drug Design, Development and Therapy · 2026-07 · Volume 20 · 1-16

DOI: 10.2147/dddt.s598274 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Drug Design, Development and Therapy, 2026-07. Verfasst von Veerendra Kumar Panuganti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Affairs, Shilpa Medicare Limited, Hyderabad, Telangana, 500076, India. Hauptthemen laut MEDLINE: Serum Albumin, Serum Albumin, Human. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Serum AlbuminSerum Albumin, HumanAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultDose-Response Relationship, DrugHealthy VolunteersRecombinant Proteins

Stichwörter der Autor:innen

Pichia pastorisalbuminbioequivalenceimmunogenicitypharmacodynamicspharmacokineticsphase irecombinant proteinssafety

Substanzen

Recombinant ProteinsSerum AlbuminSerum Albumin, Human

Autor:innen und Institutionen

  • Clinical Affairs, Shilpa Medicare Limited, Hyderabad, Telangana, 500076, India.
  • Medical Affairs Department, Shilpa Medicare Limited, Hyderabad, Telangana, 500076, India.
  • Shilpa Biologicals Private Limited, Dharwad, Karnataka, 580011, India.
  • Bioanalytical Laboratory, Shilpa Medicare Ltd, Hyderabad, Telangana, 500076, India.

ORCID-Profile: Javeed Mohammad

Zitieren

APA

Panuganti, V. K., Dundigalla, M. R., Grandhi, V. R., Khambhampaty, S., Madala, P. K., Mohammad, J., Shaik, A., Shaik, M. B., Kssvv, S., & Sangeetham, S. K. (2026). Phase I Study Evaluating Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Recombinant Human Serum Albumin (rHSA) in Healthy Adults. Drug Design, Development and Therapy, Volume 20, 1-16. https://doi.org/10.2147/dddt.s598274

Vancouver

Panuganti VK, Dundigalla MR, Grandhi VR, Khambhampaty S, Madala PK, Mohammad J, et al. Phase I Study Evaluating Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Recombinant Human Serum Albumin (rHSA) in Healthy Adults. Drug Design, Development and Therapy. 2026;Volume 20:1-16. doi:10.2147/dddt.s598274

BibTeX
@article{Panuganti2026,
  author = {Panuganti, Veerendra Kumar and Dundigalla, Mamatha Reddy and Grandhi, Venkata Ramalingayya and Khambhampaty, Sridevi and Madala, Pavan Kumar and Mohammad, Javeed and Shaik, Althaf and Shaik, Mahaboob Basha and Kssvv, Sanyasirao and Sangeetham, Sai Kumar},
  title = {Phase I Study Evaluating Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Recombinant Human Serum Albumin (rHSA) in Healthy Adults},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--16},
  doi = {10.2147/dddt.s598274}
}
Kostenlos starten →